Document 0035 DOCN M95A0035 TI Kaposi's sarcoma: a reevaluation. DT 9510 AU Orfanos CE; Husak R; Wolfer U; Garbe C; Department of Dermatology, University Medical Center Steglitz,; Free University of Berlin, Germany. SO Recent Results Cancer Res. 1995;139:275-96. Unique Identifier : AIDSLINE MED/95320439 AB Kaposi's sarcoma (KS) is a multicentric neoplasia of microvascular origin arising during development of immunodeficiency in human immunodeficiency virus (HIV)-infected individuals. More than 130 patients with HIV-associated KS (98% male homosexuals; median age, 35 years) have been diagnosed at the Department of Dermatology, University Medical Center Steglitz, Berlin, during the years 1982-1992. Mucocutaneous and visceral involvement was a common finding in patients with HIV-associated KS, increasing from 39% at the first visit to 65% at the last observation. In 90% of the patients significant immunosuppression was found (75% had a CD4+ count < 200/mm3) at the time of first diagnosis. However, immunosuppression was not a prerequisite for the development of KS, since the tumor had been diagnosed before severe immunosuppression was present in about 10% of the patients. Significant prognostic predictors for the final outcome were: (a) the degree of immunosuppression, (b) the presence of mucosal and visceral manifestation, and (c) the past history of opportunistic infections. The median survival time was 28 months in KS patients with more than 300 CD4+ lymphocytes (n = 18), but only 14 months in immunosuppressed (less than 300 CD4+ lymphocytes) individuals with KS (n = 70). The median survival time in the entire group evaluated (n = 89 patients) was 17 months after first diagnosis. In 71 HIV-infected individuals who died at the Berlin Department during the last 8 years, disseminated KS was the major direct or indirect cause of death (49% of cases). Therapeutic benefit for KS patients was observed after long-term administration of recombinant interferon alpha (rIFN-alpha; 9-18 million IU s.c. every 2 days) alone or combined with antiretroviral drugs such as zidovudine over several months. Prolongation of survival was found after such treatment modalities in 30%-40% of treated patients. Bleomycin and vincristine and other systemically used cytostatics have also been applied with moderate results. The etiology of HIV-associated KS is still unknown and coinfection with herpes simplex virus (HSV), cytomegalovirus (CMV), or human papillomavirus (HPV) as well as certain growth-stimulating cytokines (transforming growth factors, TGF; tumor necrosis factor alpha, TNF-alpha; interleukin-6, IL-6; tat; vascular endothelial growth factors, VEGF; oncostatin M) produced by HIV-infected cells may be cofactors. Overall, KS was found to be a tumor with high malignant potential, and the median survival times were short.(ABSTRACT TRUNCATED AT 400 WORDS) DE Acquired Immunodeficiency Syndrome/*COMPLICATIONS/DRUG THERAPY Adult Antineoplastic Agents, Combined/THERAPEUTIC USE AIDS-Related Opportunistic Infections/EPIDEMIOLOGY Biological Response Modifiers/THERAPEUTIC USE Combined Modality Therapy Comorbidity Follow-Up Studies Germany/EPIDEMIOLOGY Homosexuality, Male Human Immunocompromised Host Interferon Alfa, Recombinant/THERAPEUTIC USE Male Palliative Treatment Prognosis Risk *Sarcoma, Kaposi's/DIAGNOSIS/EPIDEMIOLOGY/ETIOLOGY/PATHOLOGY/ THERAPY Skin Diseases/EPIDEMIOLOGY *Skin Neoplasms/DIAGNOSIS/EPIDEMIOLOGY/ETIOLOGY/PATHOLOGY/THERAPY Survival Analysis Viscera/PATHOLOGY Zidovudine/THERAPEUTIC USE JOURNAL ARTICLE REVIEW REVIEW, ACADEMIC REVIEW, TUTORIAL SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).